Natco Pharma climbs 10 per cent on DCGI approval to begin production of 'Black Fungus' drug
Natco Pharma climbs 10 per cent on DCGI approval to begin production of 'Black Fungus' drug

Natco Pharma climbs 10 per cent on DCGI approval to begin production of 'Black Fungus' drug

Anthony Fernandes Article rating: 4.3

The shares of Natco Pharma climbed over 10 per cent intraday on May 24, 2021, following the Drug Controller General of India (DCGI) approval to begin production of antifungal drug Amphotericin B liposomal injection, which is believed to be critical in the treatment of Mucormycosis, also called 'Black Fungus'. 

Five stocks witnessing long built-up
Five stocks witnessing long built-up

Five stocks witnessing long built-up

Ganesh Pawar Article rating: 3.9

The market opened in green on May 24, 2021, overall volumes in futures & options currently stand at 3,03,89,662 contracts with a turnover of Rs. 28,37,984.68 crore.

Five stocks witnessing short built-up
Five stocks witnessing short built-up

Five stocks witnessing short built-up

Ganesh Pawar Article rating: 3.8

The market opened in green on May 24, 2021, overall volumes in futures & options currently stand at 3,03,89,662 contracts with a turnover of Rs. 28,37,984.68 crore.

Renaissance Global partners with Lao Feng Xiang to introduce Disney licensed brands in China
Renaissance Global partners with Lao Feng Xiang to introduce Disney licensed brands in China

Renaissance Global partners with Lao Feng Xiang to introduce Disney licensed brands in China

Apurva Joshi Article rating: 5.0

Renaissance Global Limited (RGL) has informed the bourses about its partnership with the second largest Chinese jewelry retailer Lao Feng Xiang (LFX) for the Chinese market for the introduction of its highly successful ‘Enhanced Disney Fine Jewelry Collection’.

RSS
First21912192219321942196219821992200Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR